Alzheimer's disease treatment with targeted therapy (Aduhelm)

Targeted therapy for Alzheimer's disease aims to interrupt the supply of vital elements (proteins, etc. ) necessary to develop symptoms further. As modern scientists confirmed the relation between the increased number of beta-amyloid plaques in the brain tissues and the severity of symptoms, medical practitioners began to create medications that could help interrupt the plague development process. Aduhelm (aducanumab) is one of the few FDA-approved medications for Alzheimer's disease targeted therapy. Aduhelm can help decrease the number of specific fractions of beta-amyloid used to develop plague. However, the patient's brain keeps producing beta-amyloid of other types during the treatment with Aduhelm. Aducanumab shows an ability to decrease the speed of Alzheimer's disease symptoms development for patients in the early stages of the disease. Aduhelm is usually administered every four weeks via intravenous infusions. Each procedure takes up to one hour. The total number of required intravenous infusions might vary depending on the severity of symptoms. Often, patients might receive additional symptomatic treatment during targeted therapy that can help to decrease the severity of possible side effects and help to cope with specific Alzheimer's symptoms more effectively.